Press Releases

Company News
Oct 28, 2020
Amendment Extends NDA Acceptance Date and Expands Agreement PALATINE, Ill. , Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product
Aug 14, 2020
PALATINE, Ill. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product
Jun 29, 2020
PALATINE, Ill. , June 29, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product
Mar 30, 2020
PALATINE, Ill. , March 30, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced
Mar 23, 2020
PALATINE, Ill. , March 23, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), today announced that Abuse Deterrent Pharma, LLC , its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acura’s LIMITx™ Technology), has engaged Catalent Pharma Solutions, LLC
Feb 28, 2020
PALATINE, Ill. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse,
Feb 10, 2020
PALATINE, Ill. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced
Jan 02, 2020
PALATINE, Ill. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today provided an update on its development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the
Oct 01, 2019
PALATINE, Ill. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced,
Sep 16, 2019
PALATINE, Ill. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced
Sep 09, 2019
PALATINE, Ill. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today announced that it has engaged Catalent Pharma Solutions, LLC (“Catalent”) to initiate manufacturing scale-up of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets to ultimately be used in
Jul 02, 2019
Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million , not including Royalties PALATINE, Ill. , July 02, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization
Nov 27, 2018
PALATINE, Ill. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018 .
Oct 09, 2018
PALATINE, Ill. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) , a specialty pharmaceutical company focused on innovating abuse deterrent drugs , today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million
Aug 14, 2018

PALATINE, Ill. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018 . The Company reported a net loss of $2.8 million or

Jun 29, 2018

PALATINE, Ill. , June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018 . The Company reported for the first quarter 2018 a net

Jun 07, 2018

PALATINE, Ill. , June 07, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017 .